August 12, 2019 07:47 AM EDT
FDA+

FDA so­lic­its in­dus­try in­put for OND pol­i­cy pri­or­i­ties

Ana Mulero

A Fri­day FDA no­tice is so­lic­it­ing pol­i­cy sug­ges­tions from the in­dus­try that re­view staff at the FDA’s Of­fice of New Drugs (OND) can im­ple­ment in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

High­lights from #AS­CO25; Biotech’s icy mar­ket; Sanofi’s $9B ac­qui­si­tion; and more

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times